

DAFTAR PUSTAKA

- Aaron, S. D., Vandemheen, K. L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O'Donnell, D., McIvor, A., Sharma, S., Bishop, G., Anthony, J., Cowie, R., Field, S., Hirsch, A., Hernandez, P., Rivington, R., Road, J., Hoffstein, V., Hodder, R., ... Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium, 2007, Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. *Annals of internal medicine*, 146(8), 545–555, <https://doi.org/10.7326/0003-4819-146-8-200704170-00152>.
- Afonso, A. S., Verhamme, K. M., Sturkenboom, M. C., & Brusselle, G. G., 2011, COPD in the general population: prevalence, incidence and survival. *Respiratory medicine*, 105(12), 1872–1884, <https://doi.org/10.1016/j.rmed.2011.06.012>.
- Agusti, A., Böhm, M., Celli, B., Criner, G. J., Garcia-Alvarez, A., Martinez, F., Sin, D. D., & Vogelmeier, C. F., 2023, GOLD COPD DOCUMENT 2023: a brief update for practicing cardiologists, *Clinical research in cardiology : official journal of the German Cardiac Society*, 1–10, <https://doi.org/10.1007/s00392-023-02217-0>.
- Alqahtani, J. S., Aldabayan, Y. S., Aldhahir, A. M., Al Rajeh, A. M., Mandal, S., & Hurst, J. R., 2021, Predictors of 30- and 90-Day COPD Exacerbation Readmission: A Prospective Cohort Study, *International journal of chronic obstructive pulmonary disease*, 16, 2769–2781. <https://doi.org/10.2147/COPD.S328030>.
- Amin, A., Khan, M. I., Khan, Z., & Khan, A., 2012, Effectiveness of oral bronchodilators in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis, *American Journal of Respiratory and Critical Care Medicine*, 186(4), 427–436.
- Appleton, S., Jones, T., Poole, P., Pilotto, L., Adams, R., Lasserson, T. J., Smith, B., & Muhammad, J., 2006, Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. *The Cochrane database of systematic reviews*, 2006(2), CD001387, <https://doi.org/10.1002/14651858.CD001387.pub2>
- Aryal, S., Guzman, E.D., & Mannino, D.M., 2014, Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes, *International Journal of COPD*, 9, 1145–1154.
- Blais, L., Forget, A., & Ramachandran, S., 2010, Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence, *Clinical therapeutics*, 32(7), 1320–1328, <https://doi.org/10.1016/j.clinthera.2010.06.022>.

- Bourbeau, J., Doiron, D., Biswas, S., Smith, B. M., Benedetti, A., Brook, J. R., Aaron, S. D., Chapman, K. R., Hernandez, P., Maltais, F., Marciniuk, D. D., O'Donnell, D., Sin, D. D., Walker, B., Dsilva, L., Nadeau, G., Coats, V., Compton, C., Miller, B. E., Tan, W. C., 2022, Ambient Air Pollution and Dysanapsis: Associations with Lung Function and Chronic Obstructive Pulmonary Disease in the Canadian Cohort Obstructive Lung Disease Study, *American journal of respiratory and critical care medicine*, 206(1), 44–55, <https://doi.org/10.1164/rccm.202106-1439OC>.
- Brashier, B. B., & Kodgule, R., 2012, Risk factors and pathophysiology of chronic obstructive pulmonary disease (COPD)., *The Journal of the Association of Physicians of India*, 60 Suppl, 17–21.
- Burgel, P. R., Paillasseur, J. L., & Roche, N., 2014, Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities, *BioMed research international*, 420134, <https://doi.org/10.1155/2014/420134>.
- Cazzola, M., & Molimard, M., 2010, The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD, *Pulmonary pharmacology & therapeutics*, 23(4), 257–267, <https://doi.org/10.1016/j.pupt.2010.03.003>.
- Cazzola, M., Rogliani, P., Calzetta, L., Hanania, N. A., & Matera, M. G., 2017, Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. *COPD*, 14(5), 552–563, <https://doi.org/10.1080/15412555.2017.1347918>.
- Chaouat, A., Naeije, R., & Weitzenblum, E., 2008, Pulmonary hypertension in COPD. *The European respiratory journal*, 32(5), 1371–1385, <https://doi.org/10.1183/09031936.00015608>.
- Chapman K. R., 2004, Chronic obstructive pulmonary disease: are women more susceptible than men?, *Clinics in chest medicine*, 25(2), 331–341. <https://doi.org/10.1016/j.ccm.2004.01.003>.
- Chen, J., Wu, Y., Zhang, X., Wang, Y., Li, J., & Zhang, Y., 2018, Body mass index and risk of exacerbation in COPD: a pooled analysis of individual participant data from 14 observational studies, *The Lancet Respiratory Medicine*, 6(1), 49–58.
- Chen, G., Lin, Q., Zhuo, D., & Cui, J., 2022, Elevated Blood Glucose is Associated with Severe Exacerbation of Chronic Obstructive Pulmonary Disease, *International journal of chronic obstructive pulmonary disease*, 17, 2453–2459, <https://doi.org/10.2147/COPD.S378259>.
- Cope, S., Kraemer, M., Zhang, J., Capkun-Niggli, G., & Jansen, J. P., 2012, Efficacy of indacaterol 75 µg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis, *International journal of chronic obstructive pulmonary disease*, 7, 415–420, <https://doi.org/10.2147/COPD.S31526>.
- Dahlan, M. Sopiudin, 2010, *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*, Salemba Medika, Jakarta.

- DiPiro J.T., Yee G.C., Posey L.M., Haines S.T., Nolin T.D., Ellingrod, V, 2020, *Pharmacotherapy: A Pathophysiologic Approach*, Eleventh Edition, McGraw Hill, New York.
- Dong, Y. H., Hsu, C. L., Li, Y. Y., Chang, C. H., & Lai, M. S., 2015, Bronchodilators use in patients with COPD, *International journal of chronic obstructive pulmonary disease*, 10, 1769–1779. <https://doi.org/10.2147/COPD.S86198>.
- Enderina, G., Andrianison, Christianto, E., 2016, Gambaran Status Gizi Pada Pasien Penyakit Paru Obstruktifkronik (Ppok) Di Rawat Inap Rsud Arifin Achmad Pekanbaru, *Jurnal Online Mahasiswa FK Unri*, 3(2), 1-9.
- Firman, I., Sartika, 2022, Studi Tingkat Penggunaan Antibiotik Untuk Pasien ISPA Di Instalasi Rawat Jalan BBKPM Makassar Periode Oktober–Desember 2017, *INHEALTH : INDONESIAN HEALTH JOURNAL*, 1(1), 1–10, <https://doi.org/10.56314/inhealth.v1i1.17>.
- GBD 2015 Chronic Respiratory Disease Collaborators, 2017, Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015, *The Lancet. Respiratory medicine*, 5(9), 691–706, [https://doi.org/10.1016/S2213-2600\(17\)30293-X](https://doi.org/10.1016/S2213-2600(17)30293-X).
- Global Initiative for Chronic Obstructive Lung Disease, 2023, *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease*, 2023 Report, Global Initiative for Chronic Obstructive Lung Disease Inc.
- Goel, M. K., Khanna, P., & Kishore, J., 2010, Understanding survival analysis: Kaplan-Meier estimate. *International journal of Ayurveda research*, 1(4), 274–278, <https://doi.org/10.4103/0974-7788.76794>.
- Hall, J. E., 2018, *Guyton dan Hall; Buku Ajar Fisiologi Kedokteran Edisi 13*, Elsevier, Singapura.
- Halpin, D. M., Gray, J., Edwards, S. J., Morais, J., & Singh, D., 2011, Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials, *International journal of clinical practice*, 65(7), 764–774. <https://doi.org/10.1111/j.1742-1241.2011.02685.x>
- Hanania, N. A., Crater, G. D., Morris, A. N., Emmett, A. H., O'Dell, D. M., & Niewoehner, D. E., 2012, Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD, *Respiratory medicine*, 106(1), 91–101, <https://doi.org/10.1016/j.rmed.2011.09.002>
- Harlan, J., 2017, *Analisis Survival*, Penerbit Gunadarma, Depok.
- Hozawa, S., Terada, M., & Hozawa, M., 2014, Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid

- monotherapy, *Pulmonary pharmacology & therapeutics*, 27(2), 190–196, <https://doi.org/10.1016/j.pupt.2013.12.003>.
- Ige, O. M., & Okesola, A. O., 2015, Comparative Efficacy And Safety Of Cefixime And Ciprofloxacin In The Management Of Adults With Community-Acquired Pneumonia In Ibadan, Nigeria, *Annals of Ibadan postgraduate medicine*, 13(2), 72–78.
- Ikawati, Zullies, 2016, *Penatalaksanaan Terapi Penyakit Sistem Pernafasan*, Bursa Ilmu, Yogyakarta.
- Inoue, D., Watanabe, R., & Okazaki, R., 2016, COPD and osteoporosis: links, risks, and treatment challenges, *International journal of chronic obstructive pulmonary disease*, 11, 637–648, <https://doi.org/10.2147/COPD.S79638>.
- Janson, C., 2020, Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease, *Journal of thoracic disease*, 12(4), 1561–1569, <https://doi.org/10.21037/jtd.2020.02.51>.
- Katzung, Bertram G., 2012, *Farmakologi Dasar dan Klinik Edisi 10*, EGC, Jakarta
- Kemenkes, 2016, *Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016 tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016-2019*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kemenkes RI, 2018, *Hasil Riset Kesehatan Dasar (Riskesdas) 2018*, Badan Penelitian dan Pengembangan Kesehatan Kementerian RI, Jakarta
- Kemenkes RI, 2019, *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Penyakit Paru Obstruktif Kronis*, Menteri Kesehatan Republik Indonesia, Jakarta.
- Kim H.C., Moffarrahi M., Hussain S.N.A., 2008, Skeletal Muscle Dysfunction in patient with Chronic Obstructive Pulmonary Disease, *International journal of COPD*, 3(46), 37-58.
- Klenbaum, D.G & Klei, M., 2005, *Survival Analysis A Self-Learning Text (second)*, Springer, New York.
- Ko, F. W., Chan, K. P., Hui, D. S., Goddard, J. R., Shaw, J. G., Reid, D. W., & Yang, I. A., 2016, Acute exacerbation of COPD. *Respirology (Carlton, Vic.)*, 21(7), 1152–1165, <https://doi.org/10.1111/resp.12780>.
- Lai, C. C., Chen, C. H., Lin, C. Y. H., Wang, C. Y., & Wang, Y. H., 2019, The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials, *International journal of chronic obstructive pulmonary disease*, 14, 1539–1548, <https://doi.org/10.2147/COPD.S200846>.
- Langham, S., Lewis, J., Pooley, N., Embleton, N., Langham, J., Han, M. K., & Chalmers, J. D., 2019, Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review. *Respiratory research*, 20(1), 242, <https://doi.org/10.1186/s12931-019-1213-9>.
- Larsson K., 2007, Aspects on pathophysiological mechanisms in COPD, *Journal of internal medicine*, 262(3), 311–340, <https://doi.org/10.1111/j.1365-2796.2007.01837.x>.

- Larsson, K., Janson, C., Lisspers, K., Jørgensen, L., Stratelis, G., Telg, G., Ställberg, B., & Johansson, G., 2013, Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study, *Journal of internal medicine*, 273(6), 584–594. <https://doi.org/10.1111/joim.12067>.
- Lee, A. L., & Goldstein, R. S., 2015, Gastroesophageal reflux disease in COPD: links and risks. *International journal of chronic obstructive pulmonary disease*, 10, 1935–1949, <https://doi.org/10.2147/COPD.S77562>.
- Lee, H. W., Park, J., Jo, J., Jang, E. J., & Lee, C. H., 2019, Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis, *PLoS medicine*, 16(11), e1002958. <https://doi.org/10.1371/journal.pmed.1002958>.
- Lemeshow S., Hosmer D.W., Klar J., Lwanga S.K., 1997, *Besar Sampel dalam Penelitian Kesehatan*, Gadjah Mada University, Yogyakarta.
- Li, H., He, G., Chu, H., Zhao, L., & Yu, H., 2003, A step-wise application of methylprednisolone versus dexamethasone in the treatment of acute exacerbations of COPD. *Respirology (Carlton, Vic.)*, 8(2), 199–204, <https://doi.org/10.1046/j.1440-1843.2003.00468.x>.
- Li, K., Liu, L., & Ou, Y., 2022, The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies, *Journal of cardiothoracic surgery*, 17(1), 266, <https://doi.org/10.1186/s13019-022-01882-y>.
- Lipson, D. A., Barnhart, F., Brealey, N., Brooks, J., Criner, G. J., Day, N. C., Dransfield, M. T., Halpin, D. M. G., Han, M. K., Jones, C. E., Kilbride, S., Lange, P., Lomas, D. A., Martinez, F. J., Singh, D., Tabberer, M., Wise, R. A., Pascoe, S. J., & IMPACT Investigators, 2018, Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD, *The New England journal of medicine*, 378(18), 1671–1680, <https://doi.org/10.1056/NEJMoa1713901>.
- Loke, W. S., Herbert, C., & Thomas, P. S., 2013, Sarcoidosis: Immunopathogenesis and Immunological Markers, *International journal of chronic diseases*, 2013, 928601, <https://doi.org/10.1155/2013/928601>.
- MacNee, W., 2006, Pathology, pathogenesis, and pathophysiology, *BMJ : British Medical Journal*, 332(7551), 1202–1204.
- MacNee W., 2016, Is Chronic Obstructive Pulmonary Disease an Accelerated Aging Disease?, *Annals of the American Thoracic Society*, 13 Suppl 5, S429–S437, <https://doi.org/10.1513/AnnalsATS.201602-124AW>.
- Mandell LA, W. R., 2007, Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults, *IDSA/ATS Guidelines for CAP in Adults*, 27-72.
- Maselli, D. J., & Hanania, N. A., 2018, Asthma COPD overlap: Impact of associated comorbidities. *Pulmonary pharmacology & therapeutics*, 52, 27–31, <https://doi.org/10.1016/j.pupt.2018.08.006>.

- Miravittles, M., Guerrero, T., Mayordomo, C., Sánchez-Agudo, L., Nicolau, F., & Segú, J. L., 2000, Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis, The EOLO Study Group, *Respiration; international review of thoracic diseases*, 67(5), 495–501, <https://doi.org/10.1159/000067462>.
- Muro, S., Sugiura, H., Darken, P., & Dorinsky, P., 2021, Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts, *Respiratory research*, 22(1), 187. <https://doi.org/10.1186/s12931-021-01773-1>.
- Niewoehner, D. E., Lokhnygina, Y., Rice, K., Kuschner, W. G., Sharafkhaneh, A., Sarosi, G. A., Krumpe, P., Pieper, K., & Kesten, S., 2007, Risk indexes for exacerbations and hospitalizations due to COPD, *Chest*, 131(1), 20–28, <https://doi.org/10.1378/chest.06-1316>.
- Permatasari, C.Y., 2016, *Studi Penggunaan Kortikosteroid pada Pasien Penyakit Paru Obstruksi Kronis (Ppok) Di Rsud Dr. Soetomo Surabaya*, Skripsi, Fakultas Farmasi Universitas Airlangga, Surabaya.
- Perrone, V., Sangiorgi, D., Buda, S., & Degli Esposti, L., 2016, Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting, *International journal of chronic obstructive pulmonary disease*, 11, 2749–2755. <https://doi.org/10.2147/COPD.S114554>.
- Putcha, N., Anzueto, A. R., Calverley, P. M. A., Celli, B. R., Tashkin, D. P., Metzdorf, N., Mueller, A., & Wise, R. A., 2022, Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT, *Annals of the American Thoracic Society*, 19(2), 204–213, <https://doi.org/10.1513/AnnalsATS.202006-722OC>.
- Rabe, K. F., Martinez, F. J., Ferguson, G. T., Wang, C., Singh, D., Wedzicha, J. A., Trivedi, R., St Rose, E., Ballal, S., McLaren, J., Darken, P., Aurivillius, M., Reisner, C., Dorinsky, P., & ETHOS Investigators, 2020, Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD, *The New England journal of medicine*, 383(1), 35–48, <https://doi.org/10.1056/NEJMoa1916046>.
- Rawal, G., & Yadav, S., 2015, Nutrition in chronic obstructive pulmonary disease: A review. *Journal of translational internal medicine*, 3(4), 151–154, <https://doi.org/10.1515/jtim-2015-0021>.
- Ritianingsih, N., Nurhayati, F., 2017, Lama Sakit Berhubungan dengan Kualitas Hidup Pasien Penyakit Paru Obstruksi Kronis (PPOK), *Jurnal Kesehatan Bakti Tunas Husada*, 17(1), 133-138.
- Rosdiana, 2018, Hasil Terapi dan Identifikasi Efek Samping Obat pada Penggunaan Teofilin untuk Pasien Penyakit Paru Obstruksi Kronis (PPOK) Rawat Jalan di Rumah Sakit Paru Respira Yogyakarta, Skripsi, Program Studi Farmasi Fakultas

Matematika dan Ilmu Pengetahuan Alam Universitas Islam Indonesia, Yogyakarta.

- Safiri, S., Carson-Chahhoud, K., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Ahmadian Heris, J., Ansarin, K., Mansournia, M. A., Collins, G. S., Kolahi, A. A., & Kaufman, J. S., 2022, Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019, *BMJ (Clinical research ed.)*, 378, <https://doi.org/10.1136/bmj-2021-069679>.
- Sandman, Z., & Iqbal, O. A., 2023, Azithromycin, In *StatPearls*, StatPearls Publishing.
- Sarkar, M., Srinivasa, Madabhavi, I., Kumar, K., 2017, Tuberculosis associated chronic obstructive pulmonary disease, *The Clinical Respiratory Journal*, 11, 285-295.
- Seemungal, T. A., Hurst, J. R., & Wedzicha, J. A., 2009, Exacerbation rate, health status and mortality in COPD--a review of potential interventions, *International journal of chronic obstructive pulmonary disease*, 4, 203-223, <https://doi.org/10.2147/copd.s3385>.
- Senderovich, H., & Yendamuri, A., 2019, Management of Breathlessness in Palliative Care: Inhalers and Dyspnea-A Literature Review, *Rambam Maimonides medical journal*, 10(1), e0006, <https://doi.org/10.5041/RMMJ.10357>.
- Shin, S. H., Kwon, S. O., Kim, V., Silverman, E. K., Kim, T. H., Kim, D. K., Hwang, Y. I., Yoo, K. H., Kim, W. J., & Park, H. Y., 2022, Association of body mass index and COPD exacerbation among patients with chronic bronchitis. *Respiratory research*, 23(1), 52, <https://doi.org/10.1186/s12931-022-01957-3>.
- Soriano, J. B., Kiri, V. A., Pride, N. B., & Vestbo, J., 2003, Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients, *American journal of respiratory medicine : drugs, devices, and other interventions*, 2(1), 67-74, <https://doi.org/10.1007/BF03256640>
- Soeroto, A.Y., dan Suryadinata, H., 2014, Penyakit Paru Obstruktif Kronik, *Ina J chest Crit and Emerg Med*, 1, 83-88.
- Soeprihatini dkk., 2019, Hubungan Penyakit Paru Obstruksi Kronik (PPOK) dengan Indeks Massa Tubuh (IMT) di Klinik Harum Melati Pringsewu Tahun 2016-2017, *Jurnal Kedokteran UNILA*, 3: 74-76.
- Stoller, J. K., & Aboussouan, L. S., 2005, Alpha1-antitrypsin deficiency. *Lancet (London, England)*, 365(9478), 2225-2236, [https://doi.org/10.1016/S0140-6736\(05\)66781-5](https://doi.org/10.1016/S0140-6736(05)66781-5).
- Suissa, S., Patenaude, V., Lapi, F., & Ernst, P., 2013, Inhaled corticosteroids in COPD and the risk of serious pneumonia, *Thorax*, 68(11), 1029-1036, <https://doi.org/10.1136/thoraxjnl-2012-202872>.
- Tamondong-Lachica, D. R., Skolnik, N., Hurst, J. R., Marchetti, N., Rabe, A. P. J., Montes de Oca, M., & Celli, B. R., 2023, GOLD 2023 Update: Implications for Clinical Practice, *International journal of chronic obstructive pulmonary disease*, 18, 745-754, <https://doi.org/10.2147/COPD.S404690>.

- Trigueros, J. A., Garin, N., Baloiara, A., Aceituno, S., Calvo, A., Prades, M., Touron, C., Martínez, A., & Torres, C., 2022, Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain, *International journal of chronic obstructive pulmonary disease*, 17, 2905–2917, <https://doi.org/10.2147/COPD.S384591>.
- Vogelmeier, C. F., Diesing, J., Kossack, N., Pignot, M., & Friedrich, F. W., 2021, COPD Exacerbation History and Impact on Future Exacerbations-8-Year Retrospective Observational Database Cohort Study from Germany, *International journal of chronic obstructive pulmonary disease*, 16, 2407–2417, <https://doi.org/10.2147/COPD.S322036>.
- Walters, J. A., Walters, E. H., & Wood-Baker, R., 2005, Oral corticosteroids for stable chronic obstructive pulmonary disease, *The Cochrane database of systematic reviews*, (3), CD005374, <https://doi.org/10.1002/14651858.CD005374>.
- Wang, Y., MacNee, W. A., Chen, S., Wang, Y., Lin, H., Zhang, L., 2022, A meta-analysis of triple therapy for chronic obstructive pulmonary disease and comorbid cardiovascular disease, *Journal of the American Medical Association*, 327(17), 1837-1847. doi:10.1001/jama.2022.11079.
- Wedzicha, J. A., Banerji, D., Chapman, K. R., Vestbo, J., Roche, N., Ayers, R. T., Thach, C., Fogel, R., Patalano, F., Vogelmeier, C. F., & FLAME Investigators, 2016, Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD, *The New England journal of medicine*, 374(23), 2222–2234, <https://doi.org/10.1056/NEJMoa1516385>.
- Whittaker, H., Rubino, A., Müllerová, H., Morris, T., Varghese, P., Xu, Y., De Nigris, E., & Quint, J. K., 2022, Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study, *International journal of chronic obstructive pulmonary disease*, 17, 427–437, <https://doi.org/10.2147/COPD.S346591>.
- William, D.M., Bourdet, S.V., 2014, Chronic Obstructive Pulmonary Disease, In: DiPiro, J., et al., (Eds), *Pharmacotherapy A Pathophysiologic Approach seventh edition*, McGraw-Hill, New York.
- Wisman, B. A., Mardhiyah, R., & Tenda, E. D., 2015, Pendekatan Diagnostik dan Tatalaksana Penyakit Paru Obstruktif Kronik GOLD D : Sebuah Laporan Kasus, *Indonesian Journal of Chest*, 2(4), 180–190.
- Wulandari, A., & Veryanti, P., 2020, Effectiveness of Bronchodilator and Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD *Journal of Pharmaceutical Science and Application*, 2(1), 17–22 <https://doi.org/10.24843/JPSA.2020.v02.i01.p03>.
- Yakar, H. I., Gunen, H., Pehlivan, E., & Aydogan, S., 2017, The role of tuberculosis in COPD, *International journal of chronic obstructive pulmonary disease*, 12, 323–329, <https://doi.org/10.2147/COPD.S116086>.
- Yu, F., Huang, Q., Ye, Y., & Zhang, L., 2022, Effectiveness of Proton-Pump Inhibitors in Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized

- Controlled Trials, *Frontiers in medicine*, 9, 841155, <https://doi.org/10.3389/fmed.2022.841155>.
- Yulianti, E., 2022, Pengaruh Pemberian Inhalasi Budesonid 160 mcg/Formoterol Fumarat 4,5 mcg Turbuhaler Dibandingkan Dengan Flutikason Propionat 250 mcg/salmeterol Xinafoat 50 mcg diskus Pada Rehospitalisasi Pasien PPOK (Penyakit Paru Obstruktive Kronik) Setelah Rawat Inap di Rumah Sakit Paru Respira, Tesis, Magister Klinik Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Zhao, D., Ling, C., Guo, Q., Jin, J., & Xu, H., 2018,. Efficacy and safety of tiotropium bromide combined with budesonide/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease. *Experimental and therapeutic medicine*, 16(6), 4578–4584. <https://doi.org/10.3892/etm.2018.6773>.
- Zheng, Y., Zhu, J., Liu, Y., Lai, W., Lin, C., Qiu, K., Wu, J., & Yao, W., 2018, Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis, *BMJ (Clinical research ed.)*, 363, k4388, <https://doi.org/10.1136/bmj.k4388>.
- Zhudenkov, K., Palmér, R., Jauhiainen, A., Helmlinger, G., Stepanov, O., Peskov, K., Eriksson, U. G., & Wählby Hamrén, U., 2021, Longitudinal FEV₁ and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling. *International journal of chronic obstructive pulmonary disease*, 16, 101–111, <https://doi.org/10.2147/COPD.S284720>.
- Zou, M., Zhang, W., Xu, Y., & Zhu, Y., 2022, Relationship Between COPD and GERD: A Bibliometrics Analysis. *International journal of chronic obstructive pulmonary disease*, 17, 3045–3059. <https://doi.org/10.2147/COPD.S391878>.
- Zysman, M., & Raheison-Semjen, C., 2022, Women's COPD, *Frontiers in medicine*, 8, 600107, <https://doi.org/10.3389/fmed.2021.600107>.